Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
about
Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of NeuroprotectionWidespread distribution of reticulon-3 in various neurodegenerative diseasesGlycated albumin: an overview of the In Vitro models of an In Vivo potential disease markerOxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiaeBiology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorderOptimization of time-course experiments for kinetic model discriminationThe sour side of neurodegenerative disorders: the effects of protein glycation.Yeast protein glycation in vivo by methylglyoxal. Molecular modification of glycolytic enzymes and heat shock proteins.Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1The role of cell cycle-mediated events in Alzheimer's disease.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatographyRedox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.Insulin glycation by methylglyoxal results in native-like aggregation and inhibition of fibril formationProducts of the Parkinson's disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survivalHeme oxygenase-1 dysregulation in the brain: implications for HIV-associated neurocognitive disorders.Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra.An association study between Heme oxygenase-1 genetic variants and Parkinson's disease.Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications.Involvement of Maillard reactions in Alzheimer disease.Oxidative stress in neurodegenerationGlyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies.NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage.Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.Role of vitamin d in Parkinson's disease.Oxidative stress and neurodegeneration.Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein.Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.Advanced glycation and lipoxidation end products--amplifiers of inflammation: the role of food.Protein expression in a Drosophila model of Parkinson's disease.The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.Effective suppression of nitric oxide production by HX106N through transcriptional control of heme oxygenase-1Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's DiseaseMicroglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics.Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons.Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches.Advanced glycation endproducts and their pathogenic roles in neurological disorders.Synaptic protein alterations in Parkinson's disease.The Lewy body in Parkinson's disease and related neurodegenerative disorders.
P2860
Q24339442-92DCC569-0DA8-4EE7-B959-E3647F76B7D8Q24610758-25B0F8AF-A7F9-4853-9057-168E036FE62BQ27012452-D3517E35-0987-4501-B8BE-3D5E245C3487Q27692067-DE83D034-DFF5-450B-A68E-475D0F29E7CAQ28392275-64AFE5A8-E95A-4A48-99E9-DD1113F34B19Q28481387-45BF46A9-A295-4073-A318-5B2B8BCE3FE8Q30386079-14C7BE66-4E02-4C0D-8AEE-B82AFA15CEA4Q33261536-126865E2-4D44-46AC-912F-EDFB7C26BE1FQ33646741-CDA892C0-FB4A-4353-BB28-13F8F417120AQ33723773-01B2D07F-7646-42B0-BBBF-C1AF629F232EQ33731321-C843C582-491C-4D25-A499-0CCED9BB2413Q33812905-8A14299B-49A6-405A-A214-7648D4ECF9D8Q33871711-0AC8424B-019B-47F3-9E21-CC17E609D867Q33984004-6924E3B3-0CE4-48CA-815E-15912C9DF6B2Q34048830-7662C3B2-CAE0-4160-9464-D9E30A4BD4E9Q34139883-EF7F2D37-A904-4E76-996A-0934DB88E86FQ34169019-0C86B125-729F-4771-8932-45EB3FF0D667Q34238382-FD9D89F5-9CB2-4AFB-9FCA-9CC5BC2263F5Q34336978-C956C553-A0AC-4F06-9EC7-B2379BED3546Q34638333-2AD3578A-38A5-4D41-95EE-0559D6B42099Q35164047-AE430053-EC0A-4D6B-89CC-3809BC88E392Q35224677-3AF770F7-09AF-4760-AAF0-39FDA0547C80Q35355392-35310E48-0C06-4F3E-95FF-672CF10B51B6Q35408649-8F6955C0-400E-49A3-B2DD-DD6CCE03F3ADQ35753534-94822F1E-55C0-40C3-A7F0-3CC41536B280Q35949729-AB322AB7-9724-4237-8B1D-81B405752133Q36203957-355F3AA8-A663-473F-A581-C085A385DFF1Q36335146-CA7C3713-8595-4D0C-9420-6ABF38AE87D1Q36732766-AE4C85F8-D22C-4982-9F48-0F182243F88BQ36915810-9CD5E734-F91E-46F1-884A-A96642385E25Q37002789-7C3981B5-962E-493E-B9C0-A02774808A5CQ37003482-6F07DDFA-A661-4188-9995-34F7DAF7240CQ37071393-AD694A04-E82D-4DB6-9D65-5BB262FB2123Q37091371-3E3C02EA-D8C6-41FF-9D01-1A2D2035F100Q37214469-95D7AB10-B3E8-466E-915B-88891C7E3BBFQ37275312-52733726-F63C-4910-B73E-84B1CA130EB4Q37462278-7358E948-0B2C-4062-90EB-15EA5FE10788Q37800424-62A89CDC-0145-4348-9153-4D73C454FA97Q37972089-45BACFA9-D766-4994-A6F7-58FB1D4059D4Q38012653-4EDCA320-20D6-49DA-8613-162F86370647
P2860
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@en
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@nl
type
label
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@en
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@nl
prefLabel
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@en
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@nl
P50
P1433
P1476
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
@en
P304
P356
10.1016/0006-8993(96)00729-9
P4011
fc991baa7b02f00b5364d2acbe8787b929bedae2
P407
P577
1996-10-01T00:00:00Z